Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function

Ignatios Ikonomidis, Dimitrios Vlastos, Gavriela Kostelli, Kallirhoe Kourea, Konstantinos Katogiannis, Maria Tsoumani, John Parissis, Ioanna Andreadou, Dimitrios Alexopoulos, Ignatios Ikonomidis, Dimitrios Vlastos, Gavriela Kostelli, Kallirhoe Kourea, Konstantinos Katogiannis, Maria Tsoumani, John Parissis, Ioanna Andreadou, Dimitrios Alexopoulos

Abstract

We compared the effects of Heat-not-Burn cigarette (HNBC) to those of tobacco cigarette (Tcig), on myocardial, coronary and arterial function as well as on oxidative stress and platelet activation in 75 smokers. In the acute study, 50 smokers were randomised into smoking a single Tcig or a HNBC and after 60 min were crossed-over to the alternate smoking. For chronic phase, 50 smokers were switched to HNBC and were compared with an external group of 25 Tcig smokers before and after 1 month. Exhaled carbon monoxide (CO), pulse wave velocity (PWV), malondialdehyde (MDA) and thromboxane B2 (TxB2) were assessed in the acute and chronic study. Global longitudinal strain (GLS), myocardial work index (GWI), wasted myocardial work (GWW), coronary flow reserve (CFR), total arterial compliance (TAC) and flow-mediated dilation (FMD) were assessed in the chronic study. Acute HNBC smoking caused a smaller increase of PWV than Tcig (change 1.1 vs 0.54 m/s, p < 0.05) without change in CO and biomarkers in contrast to Tcig. Compared to Tcig, switching to HNBC for 1-month improved CO, FMD, CFR, TAC, GLS, GWW, MDA, TxB2 (differences 10.42 ppm, 4.3%, 0.98, 1.8 mL/mmHg, 2.35%, 19.72 mmHg%, 0.38 nmol/L and 45 pg/mL respectively, p < 0.05). HNBCs exert a less detrimental effect on vascular and cardiac function than tobacco cigarettes.Trial registration Registered on https://ichgcp.net/clinical-trials-registry/NCT03452124" title="See in ClinicalTrials.gov">NCT03452124, 02/03/2018).

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Acute effects of heat-not-burn puffing versus tobacco cigarette smoking. Comparison between the acute effects of heat-not-burn versus tobacco cigarette smoking on (A) arterial stiffness, (B) oxidative stress burden, and (C) platelet activation status. HBNC showed a smaller increase of PWV than tobacco cigarette. All biomarkers are impaired following Tcig smoking, in contrast with HNBC puffing. PWV carotid-femoral pulse wave velocity, HNBC heat-not-burn cigarette, MDA malondialdehyde, Tcig tobacco cigarette, TxB2 thromboxane B2, SE Standard Error.
Figure 2
Figure 2
Progression of coronary flow reserve, flow mediated dilation, and myocardial work within 1 month of follow-up. Replacement of Tcig smoking with HNBC puffing for 1-month results in coronary and peripheral endothelial function improvement, along with wasted myocardial work reduction. CFR coronary flow reserve, FMD flow-mediated dilation, GWW global wasted work, SE Standard Error.
Figure 3
Figure 3
Coronary flow of left anterior descending artery at rest (left panel) and after adenosine infusion (right panel) for calculation of coronary flow reserve. Coronary flow of left anterior descending artery at rest (left panel) and after adenosine infusion (right panel) for calculation of coronary flow reserve at baseline (A) and after switching to HNBC for one month (B). The coronary flow reserve increased from 2.5 to 3.1 after 1 month of switching from tobacco cigarette to HNBC.
Figure 4
Figure 4
Flow chart of the study population. HNBC heat-not-burn cigarette, TCig tobacco cigarette.
Figure 5
Figure 5
Acute phase protocol. Following an initial sham smoking session, subjects were randomised to either a heat-not-burn or traditional cigarette smoking session; following a washout period of 60 min, they were crossed-over to the alternative smoking session. Each session was followed by a vascular stiffness examination and blood-sampling for oxidative stress and platelet activation assessment. Exam examination, HNBC heat-not-burn cigarette, TCig tobacco cigarette.

References

    1. Piepoli MF, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of ten societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2016;37:2315–2381. doi: 10.1093/eurheartj/ehw106.
    1. Ikonomidis I, et al. Electronic cigarette smoking increases arterial stiffness and oxidative stress to a lesser extent than a single conventional cigarette: An acute and chronic study. Circulation. 2018;137:303–306. doi: 10.1161/CIRCULATIONAHA.117.029153.
    1. Farsalinos K, Tsiapras D, Kyrzopoulos S, Voudris V. Acute and chronic effects of smoking on myocardial function in healthy heavy smokers: A study of Doppler flow, Doppler tissue velocity, and two-dimensional speckle tracking echocardiography. Echocardiography. 2013;30:285–292. doi: 10.1111/echo.12052.
    1. Celermajer DS, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149–2155. doi: 10.1161/01.cir.88.5.2149.
    1. Lupia E, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis. 2010;210:314–319. doi: 10.1016/j.atherosclerosis.2009.11.019.
    1. Townsend RR, et al. Recommendations for improving and standardizing vascular research on arterial stiffness: A Scientific Statement from the American Heart Association. Hypertension. 2015;66:698–722. doi: 10.1161/HYP.0000000000000033.
    1. Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339.
    1. Hansen TW, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. J. Hum. Hypertens. 2008;22:214–216. doi: 10.1161/CIRCULATIONAHA.105.579342.
    1. Haluska BA, Jeffriess L, Brown J, Carlier S, Marwick TH. A comparison of methods for assessing total arterial compliance. J. Hum. Hypertens. 2010;24:254–262. doi: 10.1038/jhh.2009.92.
    1. Corretti MC, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 2002;39:257–265. doi: 10.1016/s0735-1097(01)01746-6.
    1. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int. J. Cardiovasc. Imaging. 2010;26:631–640. doi: 10.1007/s10554-010-9616-1.
    1. Anantharam B, et al. Coronary flow reserve assessed by myocardial contrast echocardiography predicts mortality in patients with heart failure. Eur. J. Echocardiogr. 2011;12:69–75. doi: 10.1007/s10554-010-9616-1.
    1. Schindler TH, Dilsizian V. Coronary microvascular dysfunction: Clinical considerations and noninvasive diagnosis. JACC Cardiovasc. Imaging. 2020;13:140–155. doi: 10.1016/j.jcmg.2018.11.036.
    1. Camici PG, Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007;356:830–840. doi: 10.1056/NEJMra061889.
    1. Voigt JU, et al. Definitions for a common standard for 2D speckle tracking echocardiography: Consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J. Am. Soc. Echocardiogr. 2015;28:183–193. doi: 10.1093/ehjci/jeu184.
    1. Chan J, et al. A new approach to assess myocardial work by non-invasive left ventricular pressure–strain relations in hypertension and dilated cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging. 2019;20:31–39. doi: 10.1093/ehjci/jey131.
    1. Ikonomidis I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ. Cardiovasc. Imaging. 2014;7:619–628. doi: 10.1161/CIRCIMAGING.113.001193.
    1. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta. 2003;329:23–38. doi: 10.1016/s0009-8981(03)00003-2.
    1. Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: Does it exist? Am. J. Hematol. 2002;70:139–144. doi: 10.1002/ajh.10097.
    1. Perfetti T, Rodgman A. The complexity of tobacco and tobacco smoke. Contrib. Tobacco Res. 2013;24:215–232. doi: 10.2478/cttr-2013-0902.
    1. Stratton, K., Shetty, P., Wallace, R. & Bondurant, S. Committee to Assess the Science Base for Tobacco Harm Reduction. Board on Health Promotion and Disease Prevention, Institute of Medicine. In: The scientific basis for PREP assessment in Clearing the Smoke: Assessing the Science Base for Tobacco. (ed Stratton, K.) 140–179, . 10.17226/10029 (The National Academies Press, 2001).
    1. Shepperd CJ, Newland N, Eldridge A, et al. Changes in levels of biomarkers of exposure and biological effect in a controlled study of smokers switched from conventional cigarettes to reduced-toxicant-prototype cigarettes. Regul. Toxicol. Pharmacol. 2015;72:273–291. doi: 10.1016/j.yrtph.2015.04.016.
    1. Schaller JP, et al. Evaluation of the tobacco heating system 2.2, part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul. Toxicol. Pharmacol. 2016;81:S27–S47. doi: 10.1016/j.yrtph.2016.10.001.
    1. Gale N, et al. Changes in biomarkers of exposure on switching from a conventional cigarette to tobacco heating products: A randomized, controlled study in Healthy Japanese Subjects. Nicotine Tob. Res. 2019;21:1220–1227. doi: 10.1093/ntr/nty104.
    1. Forster M, et al. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul. Toxicol. Pharmacol. 2017;93:14–33. doi: 10.1016/j.yrtph.2017.10.006.
    1. Forster M, et al. Assessment of tobacco heating product THP1.0. Part 4: Characterisation of indoor air quality and odour. Regul. Toxicol. Pharmacol. 2017;93:34–51. doi: 10.1016/j.yrtph.2017.10.006.
    1. Salman R, et al. Free-base and total nicotine, reactive oxygen species, and carbonyl emissions from IQOS, a HEATED TOBACCO product. Nicotine Tob. Res. 2019;21:1285–1288. doi: 10.1093/ntr/nty235.
    1. Auer R, Concha-Lozano N, Jacot-Sadowski I, Cornuz J, Berthet A. Heat-not-burn tobacco cigarettes: smoke by any other name. JAMA Intern. Med. 2017;177:1050–1052. doi: 10.1001/jamainternmed.2017.1419.
    1. Bekki K, Inaba Y, Uchiyama S, Kunugita N. Comparison of chemicals in mainstream smoke in heat-not-burn tobacco and combustion cigarettes. J. UOEH. 2017;39:201–207. doi: 10.7888/juoeh.39.201.
    1. Farsalinos KE, Yannovits N, Sarri T, Voudris V, Poulas K, Leischow SJ. Carbonyl emissions from a novel heated tobacco product (IQOS): Comparison with an e-cigarette and a tobacco cigarette. Addiction. 2018;113:2099–2106. doi: 10.1111/add.14365.
    1. Li X, et al. Chemical analysis and simulated pyrolysis of tobacco heating system 2.2 compared to conventional cigarettes. Nicotine Tob. Res. 2018 doi: 10.1093/ntr/nty005.
    1. Biondi-Zoccai G, et al. Acute effects of heat-not-burn, electronic vaping, and traditional tobacco combustion cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking (SUR-VAPES) 2 Randomized Trial. J. Am. Heart Assoc. 2019;8:e010455. doi: 10.1161/JAHA.118.010455.
    1. Nabavizadeh P, et al. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tob. Control. 2018;27:s13–s19. doi: 10.1136/tobaccocontrol-2018-054325.
    1. Ikonomidis I, et al. Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. Atherosclerosis. 2017;262:123–130. doi: 10.1016/j.atherosclerosis.2017.05.012.
    1. Ikonomidis I, et al. Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. Eur. J. Heart Fail. 2015;17:1240–1251. doi: 10.1002/ejhf.403.
    1. Ikonomidis I, et al. Pulse wave velocity to global longitudinal strain ratio in hypertension. Eur. J. Clin. Invest. 2019;49:e13049. doi: 10.1111/eci.13049.
    1. Li H, Srinivasan SR, Berenson GS. Comparison of measures of pulsatile arterial function between asymptomatic younger adult smokers and former smokers: The Bogalusa Heart Study. Am. J. Hypertension. 2006;19:897–901. doi: 10.1016/j.amjhyper.2006.02.004.
    1. Narahashi T, Fenster CP, Quick MW, Lester RAJ, Marszalec W, Aistrup GL, Sattelle DB, Martin BR, Levin ED. Symposium Overview: Mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behaviour. Toxicol. Sci. 2000;57:193–202. doi: 10.1093/toxsci/57.2.193.
    1. Neunteufl T, Heher S, Kostner K, Mitulovic G, Lehr S, Khoschsorur G, Schmid RW, Maurer G, Stefenelli T. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J. Am. Coll. Cardiol. 2002;39:251–256. doi: 10.1016/s0735-1097(01)01732-6.
    1. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur. Heart J. 2006;27:2588.e3260. doi: 10.1093/eurheartj/ehl254.
    1. Lekakis J, Papamichael C, Vemmos C, Stamatelopoulos K, Voutsas A, Stamatelopoulos S. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am. J. Cardiol. 1998;81:1225–1228. doi: 10.1016/s0002-9149(98)00098-8.
    1. Ikonomidis I, Katogiannis K, Kostelli G, et al. Effects of electronic cigarette on platelet and vascular function after four months of use. Food Chem. Toxicol. 2020;25(141):111389. doi: 10.1016/j.fct.2020.111389.
    1. Deveci SE, Deveci F, Açik Y, Ozan AT. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir. Med. 2004;98:551–556. doi: 10.1016/j.rmed.2003.11.018.
    1. George J, et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. J. Am. Coll. Cardiol. 2019;75:3112–3120. doi: 10.1016/j.jacc.2019.09.067.
    1. Frati G, et al. Profiling the acute effects of modified risk products: Evidence from the SUR-VAPES (Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking) Cluster Study. Curr. Atheroscler. Rep. 2020;22:8. doi: 10.1007/s11883-020-0824-4.
    1. Ikonomidis I, et al. Association of abnormal coronary microcirculatory function with impaired response of longitudinal left ventricular function during adenosine stress echocardiography in untreated hypertensive patients. Eur. Heart. J. Cardiovasc. Imaging. 2012;13:1030–1040. doi: 10.1093/ehjci/jes071.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel